

ASX Announcement

Appointment of Dr Steven Cha as Chief Medical Officer

Sydney, Australia, 1 February 2022: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced the appointment of Dr Steven Cha, MD, as Chief Medical Officer (CMO) and a member of the Company's executive management team.

Dr Cha will lead the Company's global clinical development efforts and medical affairs at a pivotal time in our growth.

Dr Cha is a qualified Haematologist with over 16 years of experience in leading oncology drug development within the biotechnology and pharmaceutical industries. His most recent role was as CMO of California-based NKGen Biotech, focused on oncology, neurology and autoimmune disease programs. He provided the clinical strategy for all therapeutic indications, built the internal teams for execution of its clinical trials and represented the company with pharma partners, regulatory agencies and the investment community.

Prior to this he was Vice President, Oncology at Samumed, LLC, where he was responsible for building and establishing the oncology therapeutic indication and associated team, including the Clinical Development, Pre-Clinical, Toxicology, Clinical Operations, Medical Affairs, Clinical Pharmacology, and Translational Oncology Groups.

Another key piece of experience saw Dr Cha as Senior Director, Global Clinical Lead: Early Oncology Development and Clinical Research at Pfizer, where he built and led a cross functional team for prostate cancer, small cell lung cancer, breast cancer therapy. Prior to that, he was Head of Global Clinical Development for the Metastatic Breast Cancer Franchise of Puma Biotechnology.

Earlier in his career, Dr Cha was a Senior Medical Director and Clinical Lead at MEI Pharma, and Medical Director at Allergan. Prior to that Dr. Cha was at Amgen, where he was part of the team that went through successful global NDA filing with *Nplate*®, first-in-class thrombopoietin, and acquisition and integration of blinatumomab, first-in-class BiTE (Bispecific T-Cell Engager) platform to be commercialized.

Dr Cha received his Bachelor of Science in Biochemistry and Cell Biology from the University of California, San Diego and his Medical Degree from Tufts University School of Medicine, Boston. He subsequently completed his postgraduate and fellowship trainings in Hematology as well as Blood and Marrow Transplant at Stanford University School of Medicine.

Dr Cha stated: “I am excited to bring my extensive clinical development experience to the high calibre team at Imugene. Together, we can make a real difference to oncology outcomes by bringing to market our innovative pipeline of immunotherapy vaccines and oncolytic viruses”.

Welcoming Dr Cha, Imugene Managing Director and CEO Leslie Chong said: “We are fortunate to have a Chief Medical Officer of Dr Cha’s experience and reputation join our team. His extensive background in oncology clinical development with leading pharmaceutical and biotechnology companies makes him an ideal fit for Imugene at an important time in our company’s growth.”

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquires

investor@imugene.com

Media Enquires

Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical

milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer

Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia